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Abstract 
Using an adenoviral system as a delivery mediator of therapeutic gene, we investigated 
the therapeutic effects of the use of combined MDR1 shRNA and human NIS (hNIS) 
radioiodine gene therapy in a mouse colon xenograft model. In vitro uptake of Tc-99m 
sestamibi was increased approximately two-fold in cells infected with an adenovirus 
vector that expressed MDR1 shRNA (Ad-shMDR) and I-125 uptake was 25-fold higher 
in cells infected with an adenovirus vector that expressed human NIS (Ad-hNIS) as 
compared to control cells. As compared with doxorubicin or I-131 treatment alone, the 
combination of doxorubicin and I-131 resulted in enhanced cytotoxicity for both Ad-
shMDR and Ad-hNIS infected cells but not for control cells. In vivo uptake of Tc-99m 
sestamibi and Tc-99m pertechnetate was two-fold and 10-fold higher for Ad-shMDR 
and Ad-hNIS-infected tumors as compared to tumors infected with a control adenovirus 
construct that expressed β-galactrosidase (Ad-LacZ), respectively. In mice treated with 
either doxorubicin or I-131 alone, there was a slight delay in tumor growth as compared 
to mice treated with Ad-LacZ. However, combination therapy with doxorubicin and I-
131 induced further significant inhibition of tumor growth as compared with mice 
treated with Ad-LacZ. We have demonstrated successful therapeutic efficacy of 
combined MDR shRNA and hNIS radioiodine gene therapy using an adenoviral vector 
system in a mouse colon cancer model. Adenovirus-mediated cancer gene therapy using 
MDR1 shRNA and hNIS would be a useful tool for the treatment of cancer cells 
expressing multi-drug resistant genes. 
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Introduction 
The human sodium/iodide symporter (NIS) protein is an active iodide transporter.1 
Since the transfer of the NIS gene and the subsequent functional expression of NIS 
protein induce cancer cells to accumulate therapeutic radionuclides (I-131 and 188Re) 
from plasma, NIS gene transfer represents a possible type of radionuclide gene therapy. 
Several investigators have reported that human sodium/iodide symporter (hNIS) 
mediated-radionuclide gene therapy would offer a potential means of cancer therapy.2-6 
Multidrug resistance (MDR) is the most common impediment to successful 
chemotherapy for various cancers. Classic MDR is characterized by cross resistance to 
antineoplastic drugs and is caused by overexpression of the MDR1 gene that encodes P-
glycoprotein (Pgp), a member of the ATP-binding cassette (ABC) transporter 
superfamily.7 Most efforts to reverse MDR during the past decades have focused on the 
use of compounds that modulate Pgp activity. However, the efficiency of these drugs 
was difficult to assess due to inherent adverse side effects such as hypotension and heart 
failure. Moreover, tumor cells can acquire resistance to the applied chemosensitizers, 
so-called tertiary resistance. 
Experimental therapeutic strategies to reverse MDR are under investigation. These 
strategies included gene therapeutic approaches with the use of antisense 
oligonucleotides (ODNs), ribozymes or DNAzymes and, most recently, the application 
of RNA interference (RNAi) technology.8, 9 RNAi is a conserved cellular mechanism 
where double-stranded RNA (dsRNA) silences the corresponding homologous gene.8, 9 
Double-stranded small interfering RNA (siRNA) molecules with a length of 19–25 
nucleotides can direct degradation of eukaryotic mRNAs in a sequence-specific manner. 
Transient RNAi can be attained by application of small interfering RNAs (siRNAs), 
whereas stable RNAi-mediated gene silencing can be achieved by transfection of 
mammalian cells with short hairpin RNA (shRNA) encoding expression cassettes that 
are localized on plasmid or viral vectors. 
Previously, we have reported on the increased therapeutic effects of combination 
MDR1 shRNA and hNIS radioiodine gene therapy in human cancer cells in vitro using 
stable transfectants that express MDR1 shRNA for the MDR1 gene and human NIS 
(hNIS) gene.10 Although the in vitro study showed a therapeutic effect in a human colon 
cancer model, the application of our findings in a clinical setting is not straightforward. 
We have attempted to identity a new method to treat effectively drug-resistance cancer 
and mimic the clinical situation. Among various therapeutic strategies, we have focused 
on the use of adenovirus-mediated therapeutic gene delivery in an in vivo cancer model. 
An adenoviral vector is the major delivery system commonly used for gene therapy in 
vivo.11, 12 The use of an adenoviral vector system has been reported to have several 
beneficial features as compared to other viral vector systems, such as efficient 
transfection in various cells including both quiescent and dividing cells, and high level 
expression of the gene of interest by the use of a CMV promoter during the short term. 
In this study, we have attempted to demonstrate whether adenovirus-mediated 
MDR1 shRNA plus hNIS gene transfer in a human colon cancer model would be 
potentially visualized by the use of nuclear imaging and subsequently generate strong 
therapeutic effects in vivo. 
Results 
 
Increased uptake of Tc-99m sestamibi and I-125 in Ad-shMDR/Ad-hNIS-infected 
HCT-15 cells 
Increased human NIS protein expression was observed in Ad-hNIS infected cells, 
and decreased P-glycoprotein expression was found in Ad-shMDR infected cells as 
determined by Western blotting.15. In addition, a reduction of MDR1 gene expression 
was determined by RT-PCR analysis in Ad-shMDR infected cancer cells, as has been 
reported previously. 
The uptake of Tc-99m sestamibi was significantly increased in Ad-shMDR or in 
both Ad-shMDR and Ad-hNIS infected HCT-15 cells but not in parental cells (Figure. 
1a, P < 0.05) and uptake was approximately two-fold higher for the use of both 
constructs as compared to that of the parental cells. Concurrently, I-125 uptake was 26-
fold and 22-fold higher in Ad-hNIS or Ad-shMDR/Ad-hNIS-infected HCT-15 cells, 
respectively, as compared to the parental cells (Fig. 1b, P < 0.05). I-125 uptake in Ad-
hNIS-infected cells was slightly higher as compared to uptake for both Ad-hNIS and 
Ad-shMDR infected cells, but did not reach statistical significance. I-125 uptake in 
hNIS expressing cells was almost completely inhibited by treatment with perchlorate, a 
competitive NIS inhibitor. 
 
In vitro treatment with doxorubicin and I-131 
The survival rates of cells in the presence of 1 µM and 60 µM doxorubicin were 
significantly lower for Ad-shMDR or Ad-shMDR/Ad-hNIS infected cells as compared 
to non-infected-parental cells (Figure. 2a, P < 0.05). In vitro clonogenic assays 
demonstrated that viability was reduced in Ad-hNIS-infected HCT-15 cells in a dose-
dependent manner, but not in parental cells; treatment with 37 MBq I-131 markedly 
decreased viability (Figure. 2b, P < 0.05). Subsequently, combination treatment with I-
131 and doxorubicin generated more enhanced cellular cytotoxic effects in Ad-
shMDR/Ad-hNIS infected HCT-15 cells as compared to that of control cells (Figure. 3). 
Particularly, the highest cellular cytotoxicity was observed in cells treated with the 
combination of 18.5 MBq I-131 and 10 µM doxorubicin as compared to control cells 
(control cells and both 18.5 MBq I-131 and 10 µM doxorubicin treated cells, 19% and 
100%, respectively). 
 
In vivo imaging of tumors treated with both Ad-shMDR and Ad-hNIS 
Scintigraphic imaging revealed increased uptake of Tc-99m sestamibi in Ad-
shMDR/Ad-hNIS-infected tumors but not in Ad-LacZ-infected tumors (Figure. 4a). In 
addition, higher uptake of Tc-99m pertechnetate was observed in Ad-shMDR/Ad-hNIS-
infected HCT-15 tumors as compared to Ad-LacZ-infected HCT-15 tumors by the use 
of a gamma camera (Figure. 4b). Physiological uptake of Tc-99m was seen in the 
thyroid and stomach expressing hNIS. Fluorescence imaging showed an EGFP signal in 
Ad-shMDR/Ad-hNIS-infected tumors but not in Ad-LacZ-infected tumors (Figure. 4c). 
 
Immunohistological analysis of Ad-shMDR/Ad-hNIS or Ad-LacZ-infected tumors 
Immunohistological staining using anti-P-glycoprotein and anti-hNIS revealed that 
P-glycoprotein expression was reduced in Ad-shMDR/Ad-hNIS-infected tumors but not 
in Ad-LacZ-infected tumors (Figure. 5b and e), while increased expression of hNIS 
protein was only detected in Ad-shMDR/Ad-hNIS-infected tumors but not in Ad-LacZ-
infected tumors (Figure. 5 A and D). LacZ (E. coli β-galactosidase) protein expression 
was detected in Ad-LacZ infected tumors but not in Ad-shMDR/Ad-hNIS-infected 
tumors by the use of X-gal (Figure. 5c and f). 
 
In vivo therapy with doxorubicin, I-131 and doxorubicin plus I-131 
As shown in Figure 6b, weak inhibition of tumor growth was observed in a tumor 
model infected with Ad-shMDR or Ad-hNIS, followed with either I-131 or doxorubicin 
treatment alone for 21 days post-tumor challenge. For mice treated either with I-131 or 
doxorubicin, 248 ± 21% and 227 ± 21% of the initial tumor volume was determined, 
respectively. However, the tumor volume rapidly increased and reached to 380 ± 45% 
of the initial tumor volume for mice treated with PBS (PBS versus doxorubicin or I-131 
treated mice, P < 0.05, respectively). Combination therapy using doxorubicin plus I-131 
generated significant tumor growth inhibition in tumor bearing mice injected with virus 
mixture (Ad-shMDR and Ad-hNIS), and the tumor volume increased only 75 ± 23% of 
the initial tumor volume at 21 days (mice treated with PBS, I-131 and doxorubicin 
versus mice treated with doxorubicin plus I-131, P < 0.05). However, no therapeutic 
effects with either I-131 and doxorubicin treatment alone or I-131 plus doxorubicin 
were observed in the Ad-LacZ-infected-tumor model (the tumor volume increases for 
the PBS, doxorubicin, I-131 and doxorubicin plus I-131 treatment groups were 380 ± 
60%, 420 ± 77%, 416±50% and 354 ± 80%, respectively, Figure. 6c). 
Discussion 
RNA interference (RNAi) has currently been used as an valuable research tool to 
induce the suppression of specific genes of interest using small interference RNA 
(siRNA) or micro RNA (miRNA), double strand RNA (dsRNA) molecules of short 
fragments of 19–25 base pairs.9 Several reports have shown the successful regulation of 
the MDR1 gene and cancer treatment by the use of RNA interference with in vivo 
models. Wu et al. have reported that small interfering RNA-induced suppression of 
MDR1 restores sensitivity to multidrug-resistant human breast cancer cells by analysis 
of paclitaxel and doxorubicin uptake in cancer cells and by the use of methods such as 
RT-PCR analysis.16 Alexandra et al. have also demonstrated the stable and complete 
suppression of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric or 
pancreatic carcinoma cell lines using adenovirus expressing MDR1 siRNA.17. More 
recently, Xueshi et al. demonstrated suppression of MDR1 mediated-multi-drug 
resistance using a lentivirus that expressed MDR1 shRNA in human leukemia cells.18 
We have previously reported the additive therapeutic effects of the combination of 
vector-based MDR1 RNA interference and hNIS radioiodine gene therapy in human 
colon cancer cells in vitro.10 Although this new therapeutic strategy was effective in 
vitro, some problems remain to be solved for application in a clinical situation. Namely, 
a stable transfectant expressing hNIS and MDR1 shRNA is an artificial model to 
examine the therapeutic effects of the combination of hNIS radioiodine gene therapy 
and MDR1 shRNA therapy. Thus, new targeted methods should be developed where 
MDR1 shRNA and the NIS gene are only expressed in cancer models. Several 
investigators have described tissue-specific delivery methods of therapeutic genes in 
various cancer models using an adenoviral system.19-22 These investigators have 
demonstrated that an adenovirus-mediated gene delivery system can induce strong 
expression of therapeutic genes and effective anti-tumor effects in some cancer models. 
Based on these previous studies, we adopted the use of an adenovirus-mediated 
delivery system for effective expression of MDR1 shRNA and hNIS in a human colon 
cancer model, a therapeutic strategy closer to the clinical situation than that of the use of 
stable transfectants as was reported previously. Although there are some strategies for 
multiple therapeutic gene expression such as the use of a bicistronic vector (IRES) and 
the fusion vector approach23, we constructed two types of adenovirus expressing MDR1 
shRNA or the human NIS gene. An adenovirus mixture (Ad-shMDR and Ad-hNIS) was 
used for in vitro and in vivo therapy experiments. Previous studies have shown effective 
gene expression of therapeutic genes and tumor growth inhibition by co-injection of 
separate adenoviruses into tumors.24, 25 
By the use of Tc-99 sestamibi uptake analysis, we found that an adenovirus 
expressing MDR1 shRNA effectively inhibited P-glycoprotein expression and caused 
increased the uptake of Tc-99m sestamibi in infected human colon cancer cells in vitro 
or in vivo (Figure. 1A and Figure. 4). Furthermore, we observed that Ad-hNIS infection 
of cancer cells induced increased uptake of I-125 and Tc-99m pertechnetate in infected 
human colon cancer cells in in vitro and in vivo models (Figure. 1B and 4). An in vitro 
cellular cytotoxic assay showed increased cytotoxic effects with the use of combination 
therapy (doxorubicin and I-131) as compared to the use of single therapy (doxorubicin 
or I-131) (Figures. 2 and 3). More interestingly, the use of in vivo tumor therapy 
demonstrated that the adenovirus-mediated therapeutic strategies generated significant 
inhibition of tumor growth for mice treated with combination therapy while slight tumor 
growth inhibition effects were observed in mice treated with a single therapy (Figure. 6). 
The enhanced therapeutic effects in vitro and in vivo can be explained based on the 
following mechanisms. 1) Suppression of the MDR1 gene and over-expression of NIS 
promoted the uptake of radiotracers such as Tc-99m sestamibi, I-131 and Tc-99m 
pertechnetate, 2) facilitated the accumulation of a therapeutic drug such as doxorubicin 
and I-131, and subsequently 3) induced strong tumor growth inhibition in mice treated 
with combination therapy. Particularly, hNIS radioiodine gene therapy could 
concentrate the beta ray emitting therapeutic radionuclide (I-131) in tumors. Beta rays 
emitted from I-131 travel 0.2 to 2.4 mm in tissue,26 which results in the death of cells 
near hNIS expressing cancer cells by cross-fire effects. 
Although the anti-tumor effects and usefulness of combination therapy was shown 
in the experiments, we did not consider that the anti-tumor effects of combination 
therapy were related to adenovirus toxicity. Several investigators have reported toxicity 
related to adenovirus application to living organisms. For example, toxicity such as an 
increase of aspartate aminotransferase and alanine aminotransferase levels and low 
stability of the system are suggested as risk factors for the therapeutic use of an 
adenoviral vector delivery system. However, continued trials for viruses packaged into 
HEK 293 cells or local application of small particles into limited areas, as was 
performed in our study, have successfully reduced the risks of infection and other 
definitive risk factors.11, 12 As described above, a further study should be performed to 
investigate the safety of combination therapy of MDR1 shRNA therapy and hNIS 
radioiodine gene therapy using the adenoviral system. 
In conclusion, combined Ad-shMDR1 gene therapy and hNIS radioiodine gene 
therapy 1) enhanced the uptake of Tc-99m sestamibi and Tc-99m pertechnate in vitro 
and in vivo, 2) increased the cellular cytotoxic effects of doxorubicin and I-131 in vitro 
and 3) generated stronger anti-tumor effects in a mouse colon cancer model. 
Combination therapy strategies using an adenovirus-mediated method may have clinical 
potential in cancer patients who are non-responsive to conventional chemotherapy. 
Materials and Methods 
 
Cells and animals 
The human colon cancer cell line HCT-15 was maintained in RPMI 1640 containing 
20% fetal bovine serum (Hyclone, Logan, UT USA) and 50 units/ml 
streptomycin/penicillin (GibcoBRL, Grand Island, NY USA) at 37 °C in a humidified 
atmosphere containing 5% CO2. Specific pathogen-free six-week-old male BALB/c 
nude mice were obtained from SLC (Hamamatsu, Japan). 
Construction of an adenovirus vector expressing MDR1 shRNA or hNIS gene 
The shRNA sequence targeting the human MDR1 gene corresponded to the coding 
region at positions 79–99: 5`-AAGGAAAAGAAACCAACTGTC-3`) (GenBank 
accession number NM_000927). shRNA duplexes with the following sense and 
antisense sequences were used: 5`-
TCGAGCGACAGTTGGTTTCTTTTCCGCGGCCGCAGGAAAAGAAACCAACTG
TCTTTTTTCCAAA (sense) and 5`-
AGCTTTTGGAAAAAAGACAGTTGGTTTCTTTTCCTGCG GCCGCGGAAAAGA 
AACCAACTGTCGC (antisense). All of the shRNA duplexes were synthesized by 
Bioneer (Daejon, Korea) and were annealed. shRNA for targeted MDR1 mRNA was 
cloned into the Xho I and Hind III sites of the pRNAT H1-1 vector (GenScript, 
Piscataway, NJ USA) using an adenoviral vector system. 
Ad-shMDR is a recombinant adenovirus expressing the human MDR1 shRNA and 
the green fluorescent protein (GFP) gene under the control of the immediate early 
promoter of cytomegalovirus (CMV). The shuttle pRNAT H1-1 vector was 
homologously recombined with pAdEasy-1 (containing the E1–E3 viral backbone) 
vector into electro-competent BJ5183 bacteria and was selected on kanamycin LB plates. 
The complete Ad-shMDR virus was recovered by transfection of 10 µg Pac I digested 
DNA into human embryonic kidney (HEK 293) cells by a lipofectamine-based 
procedure. Adenoviruses expressing the human NIS gene were kindly provided by Dr. 
K.H. Lee. Recombinant adenoviruses encoding β-galactosidase (Ad-LacZ) were used as 
negative controls for the in vitro study. 
All viral stocks were prepared from infected human embryonic kidney cells (HEK 
293) by the use of standard procedures. After two-step purification on CsCl gradients, 
viral stocks were desalted by the use of G50 columns (Pharmacia, Orsay, France) and 
were frozen at -70 °C in PBS containing 10% glycerol. Viral titers were calculated by 
determination of the TCID50 or with the use of the adeno-X rapid titer kit (BD 
Bioscience, Palo Alto, CA USA). Titers are expressed as either multiplicity of infection 
(MOI) or as plaque forming units (PFU)/ml. 
Western Blotting 
Cells were washed twice with PBS. Cells in cold PHI buffer [50 mM Tris-HCl (pH 
8.0), 150 mM NaCl, 5 mM Na2EDTA, 0.5% NP-40, 100 μM phenylmethylsulphonyl 
fluoride, 1 μg/ml aprotinin, 1 μg/ml luepeptin, 1 mM DTT] were scraped from dishes 
and left on ice for 30 min with occasional vortexing. The lysates were cleared by 
centrifugation at 12,000 rpm for 10 min at 4 °C. Identical amounts (40 and 80 μg of 
protein) of cell lysates were resolved by 8% SDS-PAGE (polyacrylamide gel 
electrophoreseis). Proteins were transferred to nitrocellulose membranes in transfer 
buffer with or without methanol and the membranes were incubated in blocking 
solution consisting of 5% skim milk with TBST [10 mM Tris-HCl (pH 8.0), 150 mM 
NaCl and 0.1% Tween 20] at room temperature for 1 hr. The membranes were then 
immunoblotted with monoclonal anti-Pgp antibody C219 (170 kD; Calbiochem, La 
Jolla, CA USA), monoclonal anti-NIS FP5A (90 kD; Lab Vision, Fremont, CA USA), 
monoclonal anti-β actin antibody (Sigma-Aldrich, St. Louis, MO USA) and monoclonal 
anti-α tubulin antibody (Sigma-Aldrich). Enzyme-linked chemiluminescence was 
performed to measure absorbance according to the manufacturer’s protocol (ECL; 
Amersham Pharmacia Biotech, Piscataway, NJ USA). Expression of each protein was 
verified by exposure to X-ray film. 
 
In vitro Tc-99m sestamibi uptake 
Tc-99m sestamibi (MIBI) (Cardiolite; Bristol-Myers Squibb Medical Imaging, 
Columbus, OH USA) is a lipophilic cationic radiopharmaceutical for myocardial and 
cancer imaging with a gamma camera, and is believed to be transported as a common 
transport substrate by P-glycoportein (Pgp).13 The decreased intracellular level of 
substrate is due to enhanced efflux by membrane transporters,14 and reduced MIBI 
uptake in an MDR-expressing tumor is related to Pgp. 
Cells were seeded at 1 × 106 cells per well in 6-well plates one day before viral 
infection. The Tc-99m sestamibi uptake assay was performed at 48 hr after virus 
infection of 200 MOI of Ad-shMDR with or without 20 MOI of Ad-hNIS. Cells were 
washed once with 2 ml PBS and were then initiated by the addition of 0.1 ml PBS 
containing 370 kBq of Tc-99m sestamibi per well. After incubation for 30 min at 37 °C 
in 5% CO2, cells were washed two times with cold PBS. The radioactivity incorporated 
in cells was measured with a well gamma-counter (Packard Canberra, Downers Grove, 
IL USA). The radioactivity incorporated in cells was normalized for total protein, which 
was measured with a bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL 
USA). Uptake of Tc-99m sestamibi was expressed as cpm/mg protein. 
 
I -125 uptake assay 
Cells were plated at 2 × 105 cells per well in 24-well plates and iodide uptake 
experiments were performed at 48 hr after virus infection of 200 MOI of Ad-shMDR 
with or without 20 MOI of Ad-hNIS. Cells were washed once with 1 ml HBSS and then 
the iodide uptake assay was initiated by the addition of 0.5 ml HBSS containing 3.7 kBq 
carrier-free I-125 and/or 10 µM sodium iodide (specific activity, 740 MBq/mM) per 
well. After incubation with I-125 for 30 min at 37 °C, cells were washed two times with 
cold HBSS. The radioactivity of cells was quantified with a well gamma-counter 
(Packard Canberra). The radioactivity of cells was normalized for total protein and I-
125 uptake was expressed as cpm/mg protein. For the inhibition study, radioiodine 
uptake was measured after pretreatment with 50 μM potassium perchlorate for 1 hr and 
radioactivity incorporated in cells was measured. 
 
In vitro cytotoxicity of doxorubicin 
At one day before viral infection, 2 × 104 cells were seeded in 96-well plates and co-
infected with both 20 MOI of Ad-shMDR and 200 MOI of Ad-hNIS. Infected cells 
were incubated at 37 °C in a humidified atmosphere containing 5% CO2 for 48 hr in the 
presence of 0.01, 0.1, 1, 60, 250, 500 and 1000 μM doxorubicin (Sigma Aldrich). Two 
days after doxorubicin treatment, a 10 µl cell count solution (CCK-8; Dojindo, Tokyo, 
Japan) was added to the culture medium of cells treated with doxorubicin and plates 
were incubated at 37 oC for 4 hr. Absorbance was measured at a wavelength of 450 nm 
using a microplate reader and cellular viability (%) was determined. 
 
In vitro clonogenic Assay 
The clonogenic assay has been described previously.4 Briefly, non-infected cells or 
cells co-infected with both Ad-shMDR and Ad-hNIS were grown in a 75-cm2 flask and 
were incubated with either 5 ml HBSS (control) or HBSS containing 9.25 and 18.5 
MBq of I-131. At 7 hr after incubation with I-131, cells were washed twice with cold 
HBSS, trypsinized and counted. Treated cells were plated in 6-well plates (1000 
cells/well) and were incubated with or without 1 or 10 μM doxorubicin at 37 °C for one 
week. Cells were then washed twice with PBS and were stained with a crystal violet 
solution. Colonies of more than 30 cells were counted and the results are expressed as 
the percentage of surviving colonies obtained after treatment with I-131 or doxorubicin 
or I-131 plus doxorubicin as compared to cells treated only with HBSS. 
 In vivo imaging of tumor bearing mice 
A total of 1 × 107 HCT-15 cells were challenged to both thighs of nude mice. When 
the tumor volume reached approximately 100 mm3, Ad-shMDR (2 × 109 PFU) and Ad-
hNIS (1 × 109 PFU) were co-injected into the mouse tumors. Ad-LacZ was 
administered as a control. Each virus was introduced to mice by multiple injections of 
virus into each tumor. 
Two days after viral infection, 18.5 MBq Tc-99m sestamibi or Tc-99m 
pertechnetate was injected into tumor bearing mice via the tail vein. At 60 min after the 
injection of the radiotracer, scintigraphic imaging was acquired with the use of a 
multipurpose gamma camera (Infinia, GE, Milwaukee, WI USA) equipped with a 
pinhole collimator. An enhanced green fluorescent protein (EGFP) fluorescence image 
was obtained using OPtix (Advanced Research Technologies, Montreal, Canada).  
 
In vivo animal tumor therapy 
A total of 1 × 107 cells HCT-15 cells were s.c injected into both thighs of nude mice. 
When the diameter of tumors were approximately ≥ 100 mm3 (approximately 10 days 
after injection), cancer therapy was started. Mice were subdivided into four groups for 
in vivo therapy (control mice treated with PBS only, mice treated with doxorubicin, 
mice treated with I-131 and mice given combination treatment with doxorubicin and I-
131). For I-131 therapy, mice received a low-iodine diet with T4 supplementation in 
drinking water for two weeks to maximize radioiodine uptake in tumors and to reduce 
iodide uptake by the thyroid gland. Ad-shMDR (2 × 109 PFU) and Ad-hNIS (1 × 109 
PFU) was co-injected into tumors in the left thigh (for mice that underwent therapy). 
Ad-LacZ as a control was administered into tumors in the right thigh (control mice). 
Two days later, a single injection of either 55.5 MBq I-131 or 0.5 mg/kg doxorubicin 
was i.p injected once per three days for nine days. The tumor volume (length × width × 
height × 0.52) was measured at three-day intervals for 21 days. 
 
Histopathological analysis 
Tumor masses were removed from mice and were preserved in 10% formalin until 
required. All tumor masses were embedded in paraffin, sectioned at 5 μm and were 
stained with hematoxylin and eosin (H & E staining). 
For immunohistological analysis of Pgp and hNIS, the paraffin sections were 
incubated for 1 hr with anti-Pgp and anti-NIS antibodies at a 1:100 and 1:50 dilution, 
respectively. Sections were then incubated for 30 min with a goat anti-rabbit secondary 
antibody conjugated to peroxidase (Immunotech, Marseille, France). 
For immunohistological analysis of ß-galactosidase, 5 μm cryosections were washed 
with 2 ml PBS at room temperature. A 5 ml solution of cell fixative (2% formaldehyde, 
0.2% glutaraldehyde and 1× PBS) was added and the slides were then washed once with 
PBS. Slides were incubated with X-gal staining solution for 14 hr at 37 oC in the dark 
and were examined under a light microscope (magnification, ×200). 
 
Statistical analysis 
Data are presented as the mean ± standard deviation. Inter-group differences were 
assayed using the two-tailed Student’s t-test. P values of < 0.05 were considered as 
statistically significant.
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Figure Legends 
 
Figure 1. Functional uptake of Tc-99m sestamibi and I-125 in Ad-shMDR or Ad-hNIS 
infected HCT-15 cells. HCT-15 cells were infected with Ad-shMDR (200 MOI) or Ad-
shMDR (200 MOI) plus Ad-hNIS (20 MOI) for 48 hr and were incubated with 370 kBq 
Tc-99m sestamibi for 30 min (a). I-125 uptake was performed in transfected HCT15 
cells with Ad-hNIS (20 MOI) or Ad-hNIS (20 MOI) plus Ad-shMDR (100 MOI). I-125 
uptake was then initiated for 30 min by the addition of 0.5 ml HBSS containing 3.7 kBq 
of I-125 per well and was blocked in the presence of KClO4, a known inhibitor of NIS 
function (b). Results are expressed as the mean of cpm per protein concentration. The 
data shown are the means of experiments performed in triplicate. Bars represent means 
± SD; N.S, not significant;*, statistically significant 
 
Figure 2. Cytotoxic effects of doxorubicin or I-131 in Ad-shMDR and Ad-hNIS 
infected cancer cells. HCT-15 cells infected with 200 MOI Ad-shMDR and 20 MOI 
Ad-hNIS were incubated in the presence of 0, 0.01, 0.1, 1, 60, 250, 500 and 1000 µM 
doxorubicin for 48 hr at 37 °C (a). HC-T15 cells infected with 20 MOI of Ad-hNIS 
were treated with 0, 9.25, 18.5 and 37.0 MBq of I-131 in HBSS or HBSS alone for 7 hr. 
Cellular viability assessed by the use of a clonogenic assay was compared to treatment 
with I-131 or with HBSS alone (b). The data shown are the means of experiments 
performed in triplicate. Bars represent means ± SD; N.S, not significant;*, statistically 
significant 
 
Figure 3. Cellular cytotoxic effects of combined doxorubicin and I-131 in both Ad-
shMDR and Ad-hNIS infected HCT15 cells. HCT-15 cells were infected with both Ad-
shMDR (200 MOI) and Ad-hNIS (20 MOI) for 48 hr. At 48 hr after viral infection, cells 
were treated with HBSS, 9.25 MBq and 18.5 MBq of I-131 for 7 hr. I-131 treated cells 
(1000 cells/well) were incubated with or without 1 or 10 µM doxorubicin at 37 oC for 
one week. Cells were stained with a crystal violet solution and colonies of more than 30 
cells were counted. Results are expressed as the percentage of surviving colonies. The 
data shown are the means of experiments performed in triplicate. Bars represent means 
± SD. 
 
Figure 4. In vivo imaging of tumor bearing mice infected with both Ad-shMDR and 
Ad-hNIS. A total of 1 × 107 HCT-15 cells were s.c injected into both thighs of mice. 
When the tumor volume reached approximately 100 mm3, Ad-shMDR (2 × 109 PFU) 
and Ad-hNIS (1 × 109 PFU) were intratumorally injected into the tumor bearing mice. 
Ad-LacZ as a control was intratumorally injected to tumor bearing mice. At two days 
after virus injection, gamma camera imaging was performed to detect Tc-99m sestamibi 
and Tc-99m pertechnetate (a and b). A fluorescence image was obtained using the 
OPtix imaging system (c). Experiments were performed in triplicate; n = 5 mice/group. 
 
Figure 5. Histopathological analysis of both Ad-shMDR and Ad-hNIS-infected tumors. 
Extracted tumors were fixed with 4% formalin overnight. For immunohistological 
examination of Pgp and hNIS, paraffin sections (5 µm thick) were incubated with anti-
NIS (a, d) and anti-Pgp (b, e). Ad-LacZ infected tumors (control) were stained with X-
gal stain solution (c) and were examined under a light microscope (×200 magnification). 
 
Figure 6. In vivo therapy of HCT15 colon tumor xenografts. Mice were divided into 
four groups to assess combination therapy in vivo when the diameters of tumors reached 
approximately 100 mm3 (■, PBS; ▲, doxorubicin; , I-131; ●. doxorubicin plus I-131). 
A virus mixture of Ad-shMDR (2 × 109 PFU) and Ad-hNIS (1 × 109 PFU) was 
administered to mice by multiple injections of virus. Ad-LacZ as a control was 
intratumorally injected to mice by multiple injections of virus. At two days after virus 
injection, a single dose of I-131 (55.5 MBq) was injected and doxorubicin treatment 
(0.5 mg/kg) was followed at three-day intervals for 21 days (a). Tumor bearing mice 
were injected with either virus mixture (Ad-shMDR plus Ad-hNIS) (b) or Ad-LacZ (c) 
followed by treatment with PBS, doxorubicin, I-131 or doxorubicin + I-131. Tumor 
volume was measured using a caliper over time. Experiments were performed in 
triplicate, n = 8 mice/group. *, statistically significant 
 
 










